← Telix Pharmaceuticals Ltd (TLX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Telix Pharmaceuticals Ltd (TLX)
Pharmaceutical Preparations · market cap $3.8B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Telix Pharmaceuticals (TLX) is a pharmaceutical company with a market cap of approximately $3.39B trading near $10.97. The company's pipeline is concentrated in prostate cancer and renal cell carcinoma, spanning multiple radiopharmaceutical and standard-of-care assets across Phase 2 and Phase 3 trials. Key pipeline assets include 177Lu-TLX591 and 68Ga-PSMA-11 for prostate cancer indications, plus 89Zr-TLX250 PET/CT for clear cell renal cell carcinoma.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Standard of Care | Phase 3 | Metastatic Prostate Cancer |
| 177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer |
| 68Ga-PSMA-11 | Phase 3 | Biochemical Recurrence of Malignant Neoplasm of Prostate |
| 177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer |
| 89Zr-TLX250 PET/CT | Phase 3 | Clear Cell Renal Cell Carcinoma |
Price & technical context
3-month
-7.3%
6-month
+14.6%
12-month
+10.9%
52-wk range
$6.41–$12.83
vs 50-day MA
-3.4%
vs 200-day MA
+13.9%
Realized vol
55.6%
Max drawdown
-70.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TLX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.